

The role of TET proteins during development

Rita Khoueiry, Kian Peng Koh

KU Leuven Department of Development and Regeneration, Stem Cell Institute Leuven, 3000 Leuven, Belgium. **Email:** rita.khoueiry@kuleuven.be

In 2009, a new family of DNA modifying enzymes, the Tet-eleven translocation family was identified as 2-oxoglutarate (2-OG) and Fe(II)-dependent dioxygenases. This family of enzymes comprises three proteins TET1, TET2 and TET3 that share a carboxyl-terminal core catalytic domain consisting of a conserved cysteine-rich domain, a double stranded β -helix domain and binding sites for the cofactors Fe(II) and 2-oxoglutarate. At their amino-terminal region, TET1 and TET3 have a CXXC DNA-binding domain¹. Interestingly, during evolution, the segment encoding the CXXC domain of TET2 was separated from the region encoding the catalytic domain and is now encoded separately by a neighboring gene, IDAX (also called CXXC4)².

All TET proteins are oxygenases capable of oxidizing 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) and further into 5-formylcytosine (5fC) and/or 5-carboxylcytosine (5caC)^{1,3}. Since their discovery, dissecting the role of TET enzymes has been the subject of many studies which revealed their implication in DNA demethylation and gene expression regulation^{4,5}. Several routes have been described for TET-mediated active and passive DNA demethylation⁶. It was suggested that 5hmC can be diluted through replication due to the low enzymatic activity of DNMT1 on hemi-hydroxymethylated DNA⁶. By an alternative pathway, 5fC and 5caC are targeted by TDG DNA glycosylase and the base-excision-repair machinery to generate unmethylated cytosines⁶. Interestingly, cytosine oxidation products might play a role beyond functioning as transient intermediates in active DNA demethylation,

providing an additional layer to the epigenetic code⁵. Indeed oxidized mC were proposed to serve as an anchor for specific epigenetic readers, to modify the recruitment of transcription factors or mC-binding proteins, and to affect RNA polymerase II elongation rate, indicating that TET-mediated oxidation could directly regulate transcription⁵. In addition, studies showed that TETs regulate several target genes by interacting with co-activators such as OGT⁷ or co-repressors like Sin3A, PRC2⁸⁻¹⁰. Whether the catalytic activity of TET is required in such cases is not completely well defined. Nevertheless, emerging evidence, including our [study](#)¹⁰, reveal catalytic-independent functions of TET enzymes during development¹⁰⁻¹².

TET enzymes in development and diseases

Because TET enzymes are implicated in DNA demethylation, many studies focused on their role at two major waves of DNA methylation remodeling, in the early post-fertilization zygote and during primordial germ cell (PGC) specification.

PGCs, which will give rise to the oocytes or spermatozooids and show high expression of TET1 and TET2, undergo two stages of DNA demethylation. Stage I of DNA demethylation in PGCs is independent from TET enzymes' activity; however, stage II involves their catalytic function¹³. The latter occurs in the mouse particularly at E9.5-E12.5, when genome-wide DNA demethylation, erasure of genomic imprints, and large-scale chromatin remodeling are happening. At those stages, TET1 is suggested

to be critical for the regulation of a set of germline reprogramming-responsive genes involved in gamete generation, meiosis and the maintenance of DNA methylation in gonadal PGCs¹⁴. Tet3 is highly expressed in oocytes but not in PGCs. All three TETs are detectable in murine sperm cells in considerable amounts⁴. In line with that, TET enzymes are successively expressed in human spermatogenesis and their expression level is pivotal for male fertility¹⁵. Female mice lacking TET1 have smaller ovary size, reduced oocyte number, decreased fertility and present small litter size¹⁶.

After fertilization, in the zygote, the paternal genome loses its DNA methylation marks rapidly. Several studies suggested that this 5mC loss in the paternal pronuclei is attributed mostly to the activity of the maternal TET3^{17,18}. However, the latter is not essential for a normal development because ablation of maternal TET3 is compatible with embryonic development¹⁹. While maternal TET3 disappears rapidly during the first cleavages of the embryo, the expression levels of *Tet1* and *Tet2* increase during preimplantation development. Indeed, TET1 and TET2 are highly expressed in the inner cell mass (ICM) of the blastocyst and embryonic stem cells (ESCs), the *in vitro* correlate of ICM, where 5hmC is present as well^{3,20}. After implantation, while TET2 and TET3 are not detectable, TET1 expression persists in the epiblast and at lower levels in the extra-embryonic ectoderm (ExE) of embryonic stage E6.5. At the latter stage, TET1 plays non redundant functions specific to both [lineages](#)¹⁰. Afterwards, TET1 expression diminishes rapidly at E7.5 and persists only faintly in the head folds and neural tube by E8.5. TET3 expression is detectable from E8.5. After axial rotation of the embryo, expression of the three TETs progressively increases in the developing brain of E9.5-10.5¹⁰.

The physiological importance of TETs in development has been investigated using several genetic knockout (KO) mouse models. Studies have shown that constitutive deletion of *Tet3* leads to neonatal lethality²¹ and that TET2 deletion results in a normal development²². However, reports concerning TET1 KOs have been more variable depending on the mice model used, resulting in some conflicting conclusions. While two studies observed that *Tet1* KO mice are born without any apparent loss *in utero*^{23,24}, another study also targeting deletion of the C-terminal catalytic function describe partial embryonic lethality, with only 30% of the expected number of *Tet1* knockouts surviving to birth²⁵. Because in those studies TET1 KOs were generated by strategies targeting the C-terminal catalytic site, they may have allowed expression of a large N-terminal fragment (~70 kDa) and resulted in hypomorphic phenotypes requiring combined deletion of other TETs^{21,26} in order to observe a stronger phenotype. Interestingly, in a *Tet1* gene trap (GT) mice model, investigated by our group and the group of Yi Zhang^{10,16}, embryonic lethality was observed starting at E8-E9.5 with different penetrance depending on the genetic background (100% in mixed background strains and 60% in C57BL/6J incipient congenic strain). Subsequently, we validated these GT phenotypes in a new mice model that we developed by an independent targeting strategy in which the lacZ reporter cassette is inserted immediately in-frame downstream of the ATG start codon¹⁰. The latter model confirmed that TET1 can be essential for embryonic development. Briefly, our analysis¹⁰ of those two mice models with ablation in the 5' coding sequence suggests that while the catalytic domain of TET1 can be dispensable, further regulation by its N-terminal domain is critical for a proper development. This clarifies why previously reported studies showed

little or no effect of TET1 loss on embryonic development.

The functions of TET enzymes are not limited to early embryonic developmental stages and to embryonic stem cells (ESCs). Studies point towards an important role of these proteins in the brain²⁶ and hematopoietic lineages⁵; in line with that, they seem to be implicated in several diseases related to those tissues (i.e. Leukemia⁵, Alzheimer disease, Huntington's disease²⁷...).

In post-natal development, TET1 and 5hmC are abundant in the brain and TET1 has been investigated as an important contributor to brain development²⁸. Recent studies indicated that TET1 deficiency decreases 5hmC levels in brain^{29,30}, resulting in impaired hippocampal neurogenesis³¹. Abnormal TET1 expression leads to neuronal activity-regulated gene downregulation, synaptic plasticity alterations, and cognitive impairments^{32,33}. Yet, little is known about the functions of TET1 in the early embryonic development of neuronal and brain tissues.

Finally, the disruption of TET1 and TET2 in adult hematopoietic tissues leads to increased hematopoietic stem cell (HSC) function^{34,35}, variable degrees of myeloid and lymphoid alterations and defects in terminal hematopoietic lineage differentiation. For example, *Tet2*^{-/-} mice develop leukemia spontaneously³⁵. In humans, somatic alterations and mutations in *TET2* are observed in a wide range of hematological disease⁵. Even though somatic alterations of *TET1* or *TET3* are less abundant than TET2 in patients with hematological diseases, murine models combining double mutations of TET enzymes are

prone to developing late-onset B-cell lymphoma³⁴ (TET1/2 KO) or a rapid and fully penetrant myeloid leukemia within 7 weeks³⁶ (TET2/3). It is important to mention that the implication of TET enzymes in malignancies seems not to be limited to hematological cancers. Indeed, mutations of TET enzymes and modifications in 5hmC levels have been described in other cancers (i.e. gastric, prostate, liver, lung, breast cancer...)⁵. However, their direct role in such cancers still needs to be investigated.

Since their discovery, many facets of TET enzymes roles in pre- and post-natal development and their involvement in many diseases have been revealed. However, many other aspects still need to be dissected and several questions need to be answered. For example, it is important to uncover the mechanisms of actions of TET enzymes, their targeted pathways and their initiating role underlying those diseases. Moreover, it is essential to understand the impact of any deregulations in TET functions acquired during embryonic development on post-natal health. Regarding the latter, our recent study¹⁰ revealed many changes in DNA methylation at pre-gastrulation stages upon loss of TET1 (For details see our earlier [article](#) published in PDJ). Interestingly, only 40% of those changes were present at differentially expressed genes at that stage; however, the majority was associated with genes involved in diseases (i.e. Alzheimer, Huntington...). Even though the catalytic functions of TET1 at the early pre-streak embryo seem to be “dispensable” for embryonic development, they may be the basis of many post-natal diseases.

1. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science*

- 324, 930-5 (2009).
<https://doi.org/10.1126/science.1170116>
 PMid:19372391 PMCID:PMC2715015
2. Ko, M. et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. *Nature* 497, 122-6 (2013).
<https://doi.org/10.1038/nature12052>
 PMid:23563267 PMCID:PMC3643997
3. Ito, S. et al. Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine. *Science* 333, 1300-3 (2011).
<https://doi.org/10.1126/science.1210597>
 PMid:21778364 PMCID:PMC3495246
4. Wu, X. & Zhang, Y. TET-mediated active DNA demethylation: mechanism, function and beyond. *Nature reviews. Genetics* 18, 517-534 (2017).
<https://doi.org/10.1038/nrg.2017.33>
 PMid:28555658
5. Rasmussen, K.D. & Helin, K. Role of TET enzymes in DNA methylation, development, and cancer. *Genes & development* 30, 733-50 (2016)
<https://doi.org/10.1101/gad.276568.115>
 PMid:27036965 PMCID:PMC4826392
6. An, J., Rao, A. & Ko, M. TET family dioxygenases and DNA demethylation in stem cells and cancers. *Experimental & molecular medicine* 49, e323 (2017).
<https://doi.org/10.1038/emm.2017.5>
 PMid:28450733
7. Cuyas, E. et al. Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism. *Oncogene* 37, 963-970 (2018).
<https://doi.org/10.1038/onc.2017.367>
 PMid:29059169
8. Zhong, T. et al. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. *Oncogene* 36, 2345-2354 (2017).
<https://doi.org/10.1038/onc.2016.391>
 PMid:27775072 PMCID:PMC5415944
9. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. *Nature* 473, 343-8 (2011).
<https://doi.org/10.1038/nature10066>
 PMid:21490601 PMCID:PMC3408592
10. Khoueiry, R. et al. Lineage-specific functions of TET1 in the postimplantation mouse embryo. *Nature genetics* 49, 1061-1072 (2017).
<https://doi.org/10.1038/ng.3868>
 PMid:28504700
11. Xu, Y. et al. Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for *Xenopus* eye and neural development. *Cell* 151, 1200-13 (2012).
<https://doi.org/10.1016/j.cell.2012.11.014>
 PMid:23217707 PMCID:PMC3705565
12. Yan, L. et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. *Oncogene* 34, 3076-84 (2015).
<https://doi.org/10.1038/onc.2014.236>
 PMid:25088204
13. Vincent, J.J. et al. Stage-specific roles for tet1 and tet2 in DNA demethylation in primordial germ cells. *Cell stem cell* 12, 470-8 (2013).
<https://doi.org/10.1016/j.stem.2013.01.016>
 PMid:23415914 PMCID:PMC3684274
14. Hill, P.W.S. et al. Epigenetic reprogramming enables the transition from primordial germ cell to gonocyte. *Nature* 555, 392-396 (2018).
<https://doi.org/10.1038/nature25964>
 PMid:29513657
15. Ni, K. et al. TET enzymes are successively expressed during human spermatogenesis and their expression level is pivotal for male fertility. *Human reproduction* 31, 1411-24 (2016).

<https://doi.org/10.1093/humrep/dew096>

PMid:27141042

16. Yamaguchi, S. et al. Tet1 controls meiosis by regulating meiotic gene expression. *Nature* 492, 443-7 (2012).

<https://doi.org/10.1038/nature11709>

PMid:23151479 PMCID:PMC3528851

17. Gu, T.P. et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. *Nature* 477, 606-10 (2011).

<https://doi.org/10.1038/nature10443>

PMid:21892189

18. Inoue, A., Shen, L., Dai, Q., He, C. & Zhang, Y. Generation and replication-dependent dilution of 5fC and 5caC during mouse preimplantation development. *Cell research* 21, 1670-6 (2011).

<https://doi.org/10.1038/cr.2011.189>

PMid:22124233 PMCID:PMC3357997

19. Tsukada, Y., Akiyama, T. & Nakayama, K.I. Maternal TET3 is dispensable for embryonic development but is required for neonatal growth. *Scientific reports* 5, 15876 (2015).

<https://doi.org/10.1038/srep15876>

PMid:26507142 PMCID:PMC4623673

20. Ruzov, A. et al. Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian development. *Cell research* 21, 1332-42 (2011).

<https://doi.org/10.1038/cr.2011.113>

PMid:21747414 PMCID:PMC3193467

21. Kang, J. et al. Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis. *Proceedings of the National Academy of Sciences of the United States of America* 112, E4236-45 (2015).

<https://doi.org/10.1073/pnas.1510510112>

PMid:26199412 PMCID:PMC4534209

22. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. *Cancer cell* 20, 11-24 (2011).

<https://doi.org/10.1016/j.ccr.2011.06.001>

PMid:21723200 PMCID:PMC3194039

23. Dawlaty, Meelad M. et al. Tet1 Is Dispensable for Maintaining Pluripotency and Its Loss Is Compatible with Embryonic and Postnatal Development. *Cell Stem Cell* 9, 166-175 (2011).

<https://doi.org/10.1016/j.stem.2011.07.010>

PMid:21816367 PMCID:PMC3154739

24. Zhang, R.R. et al. Tet1 Regulates Adult Hippocampal Neurogenesis and Cognition. *Cell Stem Cell* 13, 1-9 (2013).

<https://doi.org/10.1016/j.stem.2013.05.006>

PMid:23770080 PMCID:PMC4474382

25. Kang, J. et al. Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis. *Proc Natl Acad Sci U S A* 112, 4236-4245 (2015).

<https://doi.org/10.1073/pnas.1510510112>

PMid:26199412 PMCID:PMC4534209

26. Santiago, M., Antunes, C., Guedes, M., Sousa, N. & Marques, C.J. TET enzymes and DNA hydroxymethylation in neural development and function - how critical are they? *Genomics* 104, 334-40 (2014).

<https://doi.org/10.1016/j.ygeno.2014.08.018>

PMid:25200796

27. Al-Mahdawi, S., Virmouni, S.A. & Pook, M.A. The emerging role of 5-hydroxymethylcytosine in neurodegenerative diseases. *Frontiers in neuroscience* 8, 397 (2014).

<https://doi.org/10.3389/fnins.2014.00397>

PMid:25538551 PMCID:PMC4256999

28. Hahn, M.A. et al. Dynamics of 5-hydroxymethylcytosine and chromatin marks in Mammalian neurogenesis. *Cell reports* 3, 291-

- 300 (2013).
<https://doi.org/10.1016/j.celrep.2013.01.011>
PMid:23403289 PMCID:PMC3582786
29. Dawlaty, M.M. et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. *Cell stem cell* 9, 166-75 (2011).
<https://doi.org/10.1016/j.stem.2011.07.010>
PMid:21816367 PMCID:PMC3154739
30. Kaas, G.A. et al. TET1 controls CNS 5-methylcytosine hydroxylation, active DNA demethylation, gene transcription, and memory formation. *Neuron* 79, 1086-93 (2013).
<https://doi.org/10.1016/j.neuron.2013.08.032>
PMid:24050399 PMCID:PMC3816951
31. Zhang, R.R. et al. Tet1 regulates adult hippocampal neurogenesis and cognition. *Cell stem cell* 13, 237-45 (2013).
<https://doi.org/10.1016/j.stem.2013.05.006>
PMid:23770080 PMCID:PMC4474382
32. Rudenko, A. et al. Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. *Neuron* 79, 1109-22 (2013).
<https://doi.org/10.1016/j.neuron.2013.08.003>
PMid:24050401 PMCID:PMC4543319
33. Loebrich, S. & Nedivi, E. The function of activity-regulated genes in the nervous system. *Physiological reviews* 89, 1079-103 (2009).
<https://doi.org/10.1152/physrev.00013.2009>
PMid:19789377 PMCID:PMC2828052
34. Cimmino, L. et al. TET1 is a tumor suppressor of hematopoietic malignancy. *Nature immunology* 16, 653-62 (2015).
<https://doi.org/10.1038/ni0815-889a>
<https://doi.org/10.1038/ni.3148>
PMid:25867473 PMCID:PMC4545281
35. Ko, M. et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. *Immunological reviews* 263, 6-21 (2015).
<https://doi.org/10.1111/imr.12239>
PMid:25510268 PMCID:PMC4617313
36. An, J. et al. Acute loss of TET function results in aggressive myeloid cancer in mice. *Nature communications* 6, 10071 (2015).
<https://doi.org/10.1038/ncomms10071>
PMid:26607761 PMCID:PMC4674670